

United States Influenza Vaccines Market Forecast 2020 - 2027

<https://marketpublishers.com/r/UE7C5F744374EN.html>

Date: August 2020

Pages: 200

Price: US\$ 2,950.00 (Single User License)

ID: UE7C5F744374EN

Abstracts

The United States influenza vaccines market is set to surpass USD 5.1 Billion by 2027.

Key Highlights:

Influenza vaccines demand is anticipated to increase in the US for 2020 – 2021 Flu Season

Emergent BioSolutions Signs Contract with Novavax to Manufacture NanoFlu

Dynavax and Mount Sinai Announce Collaboration to Progress a Universal Influenza Vaccine

AstraZeneca Ships Flumist Quadrivalent Vaccine in the US for 2020-2021 Flu Season

Other three companies (Sanofi, GSK and Seqirus) have also Commences Shipping Flu Vaccines in the US for 2020-2021 Flu Season

Report Scope:

The Market Size of the United States Influenza Vaccines Market with Seven Years Forecast

Analyses the United States Overall Persons Being Vaccinated with Influenza Vaccines with Seven Years Forecast

Examines the United States Children Being Vaccinated with Influenza Vaccines with Seven Years Forecast

Scrutinizes the United States Adults Being Vaccinated with Influenza Vaccines with Seven Years Forecast

Delivers Inclusive Insights on the Latest Pricing Trends and Analysis

Covers a Complete Analysis of the US Influenza Vaccines Production, Supply, and Allocation (By Companies)

Delivers a Comprehensive Outline of the US Influenza Vaccines Distribution and Demand

Studies the Latest Effectiveness of the Influenza Vaccines in the United States

Thoroughly Assessment of the Rapid Diagnostic Testing for the Management of Influenza

Meticulously Assesses of the Distribution Channel and Technique of the Influenza Vaccination in the United States

Detailed Insights into the Regulatory Framework of the United States Influenza Vaccines Market

Features Reimbursement Patterns of the United States Influenza Vaccines Market

Tracks Competitive Developments, Approaches, Recent Industry Developments, Mergers & Acquisitions. Collaboration, Distribution, Exclusive and Licensing Agreement

An Insightful Investigation has been done on Promising Influenza Vaccines in the Clinical Development

Analyses the Most Recent Clinical Trials of the Influenza Vaccines between 2019 and 2020

Delivers an In-Depth Analysis of Evolving Market Trends, Drivers and Restraints of the United States Influenza Vaccines Market

A Comprehensive List of the Key Players Along with the Analysis of their Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Influenza Vaccines Market Value, and Recent Development

An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

“United States Influenza Vaccines Market Forecast 2020 - 2027” is based on an inclusive study of the entire United States influenza vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States influenza vaccines market. The study also presents a comprehensive analysis of the market dynamics and estimation of the market size over the forecast period 2020 – 2027.

The report comprehends a profound study with size in terms of both value and volume of the US influenza vaccines market. The report delivers a clear understanding of the up-to-date and future growths of the United States influenza vaccines market. The report also discovers a comprehensive investigation of the children and adults vaccinated with influenza vaccines in the United States from 2013 to 2019 and forecasts to 2027. The report also details the latest information about influenza vaccine production, supply, and allocation by major companies in the United States between 2014 – 2015 and 2020 - 2021.

An all-inclusive examination has been done on the pricing, distribution, demand, and effectiveness of the influenza vaccines in the United States. It also provides a deep and in-depth evaluation of the distribution channel and technique of the influenza vaccination in the United States.

Additionally, this up-to-date report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States influenza vaccines market. Moreover, the report analyses the most recent clinical trials review promising influenza vaccines in clinical development and rapid diagnostic testing for the management of influenza. The report also tracks and analyses competitive developments, including collaboration, merger & acquisition, distribution, exclusive and

licensing agreement, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.

The report also analyses detailed profiles of innovative and leading players with information on business overview, companies' vaccines portfolio, influenza vaccines market value, and the latest developments.

Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and the latest development.

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

Sanofi Pasteur

GlaxoSmithKline (GSK)

Seqirus (CSL Limited)

AstraZeneca

Novavax

BiondVax Pharmaceuticals Ltd.

Medicago

Moderna Inc

Pneumagen

Daiichi-Sankyo

Altimune

FluGen

Imutex

Key Questions Addressed by the Report

What is the current size of the overall influenza vaccines market in the United States?

How much will this market be worth from 2020 to 2027?

How many persons being vaccinated with influenza vaccines in the US during 2013 – 2027?

How effective is influenza (flu) shot for 2020?

What percentage of the United States do people get the flu vaccine?

What are the key marketed influenza vaccines available in the United States?

What are the major drivers of the United States influenza vaccines market?

What are the major inhibitors of the United States influenza vaccines market?

What is the reimbursement pattern in the United States influenza vaccines market?

What is the regulatory framework in the United States influenza vaccines market?

What are the major deals and agreement happenings in the United States influenza vaccines market?

What are the upcoming influenza vaccines that will have a significant impact on the market in the future?

Who are the top market players? What are their happenings, vaccines revenue, current developments, and scenarios?

Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?

How is the market predicted to develop in the future?

Contents

1. EXECUTIVE SUMMARY

2. UNITED STATES INFLUENZA VACCINES MARKET SIZE & ANALYSIS (2013 - 2027)

3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2013 - 2027)

3.1 Number of Children Vaccinated with Influenza Vaccines

3.2 Number of Adults Vaccinated with Influenza Vaccines

4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES INFLUENZA VACCINES MARKET

4.1 Market Drivers

4.2 Market Restraints

5. UNITED STATES INFLUENZA VACCINES PRICING TRENDS & ANALYSIS

6. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES)

7. UNITED STATES INFLUENZA VACCINES DISTRIBUTION & DEMAND (2010 - 2020)

8. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES (2004 – 2020)

9. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA

10. DISTRIBUTION CHANNEL & TECHNIQUE OF INFLUENZA VACCINATION IN THE UNITED STATES

11. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET

12. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET

13. MAJOR DEALS AND AGREEMENT HAPPENINGS IN THE INFLUENZA VACCINES MARKET

- 13.1 Merger & Acquisitions
- 13.2 Collaboration Deal
- 13.3 Licensing Agreement
- 13.4 Exclusive Agreement
- 13.5 Distribution Agreement

14. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT

15. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY

- 15.1 Year 2020
- 15.2 Year 2019

16. KEY PLAYERS ANALYSIS

- 16.1 Sanofi Pasteur
 - 16.1.1 Business Overview
 - 16.1.2 Influenza Vaccines Portfolio
 - 16.1.3 Influenza Vaccines Sales Value Analysis
 - 16.1.4 Promising Influenza Vaccines in the Clinical Development
 - 16.1.5 Recent Development
- 16.2 GlaxoSmithKline (GSK)
 - 16.2.1 Business Overview
 - 16.2.2 Influenza Vaccines Portfolio
 - 16.2.3 Influenza Vaccines Sales Value Analysis
 - 16.2.4 Recent Development
- 16.3 Seqirus
 - 16.3.1 Business Overview
 - 16.3.2 Influenza Vaccines Portfolio
 - 16.3.3 Influenza Vaccines Sales Value Analysis
 - 16.3.4 Promising Influenza Vaccines in the Clinical Development
 - 16.3.5 Recent Development

16.4 AstraZeneca

- 16.4.1 Business Overview
- 16.4.2 Influenza Vaccines Portfolio
- 16.4.3 Influenza Vaccines Sales Value Analysis
- 16.4.4 Recent Development

17. EMERGING PLAYERS ANALYSIS

17.1 Novavax

- 17.1.1 Business Overview
- 17.1.2 Promising Influenza Vaccines in the Clinical Development
- 17.1.3 Recent Development

17.2 BiondVax Pharmaceuticals Ltd.

- 17.2.1 Business Overview
- 17.2.2 Promising Influenza Vaccines in the Clinical Development
- 17.2.3 Recent Development

17.3 Medicago

- 17.3.1 Business Overview
- 17.3.2 Promising Influenza Vaccines in the Clinical Development
- 17.3.3 Recent Development

17.4 Moderna Inc

- 17.4.1 Business Overview
- 17.4.2 Promising Influenza Vaccines in the Clinical Development
- 17.4.3 Recent Development

17.5 Pneumagen

- 17.5.1 Business Overview
- 17.5.2 Promising Influenza Vaccines in the Clinical Development
- 17.5.3 Recent Development

17.6 Altimune

- 17.6.1 Business Overview
- 17.6.2 Promising Influenza Vaccines in the Clinical Development
- 17.6.3 Recent Development

17.7 Daiichi Sankyo

- 17.7.1 Business Overview
- 17.7.2 Promising Influenza Vaccines in the Clinical Development
- 17.7.3 Recent Development

17.8 FluGen

- 17.8.1 Business Overview
- 17.8.2 Promising Influenza Vaccines in the Clinical Development

17.8.3 Recent Development

17.9 Imutex

17.9.1 Business Overview

17.9.2 Promising Influenza Vaccines in the Clinical Development

17.9.3 Recent Development

List Of Tables

LIST OF TABLES:

Table 5–1: United States Pediatric Influenza Vaccines Price, 2020 – 2021

Table 5–2: United States Adult Influenza Vaccine Price, 2020 – 2021

Table 6–1: United States Influenza Vaccines Production, Supply, and Allocation

Table 7–1: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020

Table 7–2: Total Percentage of Influenza Vaccines Released by Week, 2018 – 2019

Table 7–3: Total Percentage of Influenza Vaccines Released by Week, 2017 – 2018

Table 7–4: Total Percentage of Influenza Vaccines Released by Week, 2016 – 2017

Table 7–5: Total Percentage of Influenza Vaccines Released by Week, 2015 – 2016

Table 7–6: Total Percentage of Influenza Vaccines Released by Week, 2014 – 2015

Table 8–1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2020

Table 9–1: Influenza Virus Testing Methods

Table 10–1: Distribution of Influenza Vaccination

Table 12–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 13–1: Merger & Acquisitions in the Influenza Vaccines Market

Table 13–2: Collaboration Deal in the Influenza Vaccines Market

Table 13–3: Licensing Agreement in the Influenza Vaccines Market

Table 13–4: Exclusive Agreement in the Influenza Vaccines Market

Table 13–5: Distribution Agreement in the Influenza Vaccines Market

Table 14–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials

Table 16–1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development

Table 16–2: Seqirus Promising Influenza Vaccines in the Clinical Development

Table 17–1: Novavax Promising Influenza Vaccines in the Clinical Development

Table 17–2: Biondvax Promising Influenza Vaccines in the Clinical Development

Table 17–3: Medicago Promising Influenza Vaccines in the Clinical Development

Table 17–4: Moderna Promising Influenza Vaccines in the Clinical Development

Table 17–5: Pneumagen Promising Influenza Vaccines in the Clinical Development

Table 17–6: Altimune Promising Influenza Vaccines in the Clinical Development

Table 17–7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development

Table 17–8: FluGen Promising Influenza Vaccines in the Clinical Development

Table 17–9: Imutex Promising Influenza Vaccines in the Clinical Development

List Of Figures

LIST OF FIGURES:

Figure 2–1: United States Influenza Vaccines Market (Million US\$),2013 – 2019

Figure 2–2: United States Influenza Vaccines Market Forecast (Million US\$),2020 – 2027

Figure 3–1: United States Total Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2013 – 2019

Figure 3–2: United States Total Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2020 – 2027

Figure 3–3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2013 – 2019

Figure 3–4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027

Figure 3–5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2013 – 2019

Figure 3–6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2020 – 2027

Figure 7–1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2020

Figure 10–1: United States Place of Influenza Vaccination for Children and Adults (Percent),2018 - 2019

Figure 16–1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US\$),2013 – 2019

Figure 16–2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US\$),2020 – 2027

Figure 16–3: GSK Influenza Vaccines Net Sales Value (Million US\$),2013 – 2019

Figure 16–4: GSK Influenza Vaccines Net Sales Value Forecast (Million US\$),2020 – 2027

Figure 16–5: Seqirus Influenza Vaccines Net Sales Value (Million US\$),2015 – 2019

Figure 16–6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US\$),2020 – 2027

Figure 16–7: AstraZeneca Influenza Vaccines Net Sales Value (Million US\$),2013 – 2019

Figure 16–8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US\$),2020 – 2027

I would like to order

Product name: United States Influenza Vaccines Market Forecast 2020 - 2027

Product link: <https://marketpublishers.com/r/UE7C5F744374EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UE7C5F744374EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970